Pay in 4 interest-free payments of $5.59 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
Segments Covered in This Report By Mechanism of Action GLP-1 Receptor Agonists Dual GIP/GLP-1 Agonists Triple or Multi-Receptor Agonists Centrally Acting Sympathomimetics Peripherally Acting Lipase Inhibitors By Drug Type Prescription Drugs OTC Drugs By Route of Administration Injectable (Weekly / Monthly) Oral Daily Pills By Distribution Channel Hospital Pharmacies Retail Pharmacies Online Pharmacies & Tele-health Platforms Weight-Loss Clinics Geography North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific China Japan India South Korea Australia Rest of Asia-Pacific Middle East and Africa GCC South Africa Rest of Middle East and Africa South America Brazil Argentina Rest of South America Data Sources, Market Sizing, and Validation Primary Research Endocrinologists, payers, pharmacists, and supply-chain executives across North America, Europe, Asia-Pacific, and the Gulf were interviewed to confirm real-world adherence, mark-ups, and production ramp-ups
Tesamorelin is another highly regarded GHRH, and its partnership with Ipamorelin is based on the same principle of clean, synergistic action
Always consult your healthcare provider before starting any new wellness or IV therapy program.
GLP-1s are predicted to become the best-selling drug class of 2024 (inclusive of diabetes and obesity) 2 The late-stage obesity pipeline is dominated by big pharma, and 8 of the top 20 pharma companies have a clinical stage asset in development The obesity pipeline has almost tripled in size since June 2023, and there are up to 6 new U.S
